fda glp-1 compounding crackdown news Report: must enforce rules on compounded GLP-1s Fmr. FDA Commissioner weighs in

This may result in sense loss, difficulty in proprioception, neuropathic pain, difficulty walking, poor balance, loss of sensation in the feet, muscle weakness, blurred vision (either due to retinopathy [27] or optic neuropathy [28] ), impaired urination, fertility problems, decreased sense of taste and smell, decreased level of consciousness, changes in reflexes, memory loss, mood swings, depression, irritability, cognitive impairment, confusion, anxiety, clumsiness, dementia, and, in more severe cases, psychosis

As noted previously, currently we do not have any large clinical trials for the treatment of HF or CKD in patients with or without T2D using GLP-1RA

It assists in counteracting free radicals in the body

SymDeo Plus: Helps fight odour-causing bacteria

The FDA also says telehealth companies are advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder